Daniel R. Chevallard
Known title: Chief Financial OfficerCIK: 0001706176
Daniel R. Chevallard's purchase track record
How the stock did after each of Daniel R. Chevallard's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since May 14, 2024
Stock higher 6 months later
33%
3 months: 33%
Median 6-month return
-53.4%
3 months: -30.7%
Beat the S&P 500
33%
median -66.2% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/27/2026 | LENZ | $64K | -30.7% | -53.4% | +21.6% |
| 11/7/2025 | LENZ | $50K | -38.1% | -56.2% | +10.0% |
| 5/14/2024 | LENZ | $50K | +47.4% | +137.0% | +14.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| LENZ | ▲ Buy | Open Market | 7,500 | $64K | 3/27/2026 | View on chart |
| LENZ | ▲ Buy | Open Market | 20 | $454 | 11/7/2025 | View on chart |
| LENZ | ▲ Buy | Open Market | 2,178 | $50K | 11/7/2025 | View on chart |
| LENZ | ▲ Buy | Open Market | 3,188 | $50K | 5/14/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
LENZ Therapeutics faces cash concerns amid low trading levels
A recent analysis highlights LENZ Therapeutics' cash position as a key point of interest for observers. The stock is currently trading near its 52-week low, with an RSI indicating oversold conditions. While analyst targets vary widely, the focus remains on the company's financial liquidity and operational sustainability.
LENZ Therapeutics faces cash concerns amid low trading levels. A recent analysis highlights LENZ Therapeutics' cash position as a key point of interest for observers. The stock is currently trading near its 52-week low, with an RSI indicating oversold conditions. While analyst targets vary widely, the focus remains on the company's financial liquidity and operational sustainability.